Giovanni Luca Beretta

Fondazione IRCCS Istituto Nazionale dei Tumori — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index4.0kcitations178works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(51), Bioactive Compounds and Antitumor Agents(22), DNA and Nucleic Acid Chemistry(15), Drug Transport and Resistance Mechanisms(15), Cancer, Lipids, and Metabolism(11)

Publications178 total

Exploring Guanidinium Group Involvement in Hordatine Interactions with the G-Quadruplex Motif Within the c-MYC Promoter Region
International Journal of Molecular Sciences·2025Open Access
Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors
Cancer Drug Resistance·2025Open Access
Extracellular vesicles isolated from adipose tissue-derived mesenchymal stromal cells as carriers for Paclitaxel delivery
Stem Cell Research & Therapy·2025· 3 citedOpen Access
Abstract 417: Identification of novel inhibitors of the deubiquitinase USP14 for targeting cisplatin-resistant ovarian carcinoma
Cancer Research·2025
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies
Drug Resistance Updates·2025· 10 citedOpen Access
PSMC6 regulation of ovarian cancer cisplatin resistance unravels a new mode for proteasome targeting
International Journal of Biological Sciences·2025Open Access
Cytotoxicity of Benzofuran-Containing Simplified Viniferin Analogues
Pharmaceuticals·2024· 2 citedOpen Access
KiSS-1 Modulation by Epigenetic Agents Improves the Cisplatin Sensitivity of Lung Cancer Cells
International Journal of Molecular Sciences·2024· 2 citedOpen Access
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma
Current Medicinal Chemistry·2024· 5 cited
Abstract 571: CRISPR/Cas9 screening identifies the proteasome subunit PSMC6 as key for the survival of cisplatin-resistant ovarian carcinoma cells
Cancer Research·2024
Special Issue: “Novel Researches and Perspectives on Prostate Cancer”
International Journal of Molecular Sciences·2024Open Access
Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance
International Journal of Molecular Sciences·2024· 10 citedOpen Access
Meet the Editorial Board Member
Current Medicinal Chemistry·2024
Deubiquitinases in Ovarian Cancer: Role in Drug Resistance and Tumor Aggressiveness
International Journal of Biological Sciences·2024· 12 citedOpen Access
Exploring the Interaction of New Pyridoquinazoline Derivatives with G-Quadruplex in the c-MYC Promoter Region
International Journal of Molecular Sciences·2023· 5 citedOpen Access
Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
Frontiers in Oncology·2023· 4 citedOpen Access
Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?
Journal of Thoracic Oncology·2023Open Access
Ferroptosis-induced Cardiotoxicity and Antitumor Drugs
Current Medicinal Chemistry·2023· 16 cited
Radiotherapy-induced ferroptosis for cancer treatment
Frontiers in Molecular Biosciences·2023· 35 citedOpen Access
Data from DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Franco Zunino(19), Nadia Zaffaroni(17), Paola Perego(16), Laura Gatti(11), Stella Tinelli(9), Sabrina Dallavalle(8), Michelandrea De Cesare(7), Lucio Merlini(6), Giacomo Cossa(5), Elisabetta Corna(5), Claudio Pisano(5), Graziella Pratesi(5), Valentina Zuco(4), Nives Carenini(4), Donato Colangelo(4), Franco Zunino(4), Sergio Penco(3), Paolo Carminati(3), Sabina Carla Righetti(3), Marzia Pennati(2)